--- title: "Evommune (EVMN) news: IPO and offering" url: "https://aibio.space/companies/evommune/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EVMN IPO and offering news: Evommune closes NYSE IPO of 10.8 million shares at $16, nets $157.0 million. Evommune, Inc. (NYSE: EVMN), United States." --- EVMN Evommune, Inc. NYSE · United States # Evommune (EVMN) news EVMN IPO and offering news Distress · 2026-09-08 ## [Evommune drops EVO756 in atopic dermatitis after phase 2b misses all endpoints](https://aibio.space/news/evommune-drops-evo756-atopic-dermatitis-after-phase-2b-misses-all/) The 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans. ## Latest Evommune news 1. 2026-07-08 Legal [Evommune CFO agrees to return $10,160 short-swing profit after July share purchase](https://aibio.space/news/evommune-cfo-agrees-return-10-160-short-swing-profit-after-july-share/) Evommune's chief financial officer disclosed a purchase that matches a May sale under the short-swing rule, and agreed to pay the company $10,160. 2. 2026-02-12 Financings [Evommune sells $125 million of stock privately at $27.88 a share](https://aibio.space/news/evommune-sells-125-million-stock-privately-27-88-share/) Evommune's $125 million private placement was followed by a failed atopic dermatitis trial; the company says its 2026 raise brought net proceeds of $117.2 million. 3. 2025-11-07 Financings [Evommune closes NYSE IPO of 10.8 million shares at $16, nets $157.0 million](https://aibio.space/news/evommune-closes-nyse-ipo-10-8-million-shares-16-nets-157-0-million/) Evommune sold 9,375,000 shares at $16.00 in its New York Stock Exchange listing, with a 30-day option on 1,406,250 more. Its most advanced drug's efficacy data come from a small Phase 2 study in a different condition than the one it is pursuing. ## Evommune at a glance - **Ticker**: EVMN - **Listing**: NYSE - **Country**: United States - **Cash, Jun 30, 2026**: $200.8 million ### Related companies - [Erasca](https://aibio.space/companies/erasca/) NASDAQ: ERAS - [Prestige Consumer Healthcare](https://aibio.space/companies/prestige-consumer-healthcare/) NYSE: PBH - [EyePoint](https://aibio.space/companies/eyepoint/) NASDAQ: EYPT - [Palatin Technologies](https://aibio.space/companies/palatin-technologies/) NASDAQ: PTN - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [Jaguar Health](https://aibio.space/companies/jaguar-health/) NASDAQ: JAGX - [Lipocine](https://aibio.space/companies/lipocine/) NASDAQ: LPCN - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) NASDAQ: ABUS ### Also on NYSE - [IQVIA HOLDINGS INC.](https://aibio.space/companies/iqvia/) IQV - [Picard Medical](https://aibio.space/companies/picard-medical/) PMI - [AbbVie](https://aibio.space/companies/abbvie/) ABBV - [Merck & Company](https://aibio.space/companies/merck-mrk-nyse/) MRK - [Bausch & Lomb](https://aibio.space/companies/bausch-lomb/) BLCO - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NUVB ## Evommune annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$13.0 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | [$7.0 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | | Research and development | [$74.0 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | [$64.2 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | | Net income (loss) | [-$68.9 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | [-$66.8 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | | Cash from operations | [-$76.4 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | [-$58.2 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | | Cash and equivalents | [$44.1 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/) | [$16.3 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | | Short-term investments | [$105.1 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/) | [$55.8 million](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $60.0 million, plus short-term investments of $140.8 million, $200.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Evommune When did Evommune go public? Our latest story on this, dated Nov 7, 2025: "Evommune closes NYSE IPO of 10.8 million shares at $16, nets $157.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/evommune-closes-nyse-ipo-10-8-million-shares-16-nets-157-0-million/). Has Evommune raised money recently? Our latest story on this, dated Feb 12, 2026: "Evommune sells $125 million of stock privately at $27.88 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/evommune-sells-125-million-stock-privately-27-88-share/). What is the ticker symbol of Evommune? Evommune, Inc. trades under the ticker EVMN on NYSE. Where is Evommune listed? Evommune, Inc. is listed on NYSE. What is the SEC CIK of Evommune? The SEC Central Index Key (CIK) for Evommune, Inc. is 2044725. Its filings are on SEC EDGAR. How many shares does Evommune have outstanding? 36,292,113 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Evommune listed under? Our directory records Evommune, Inc. under United States. What does Evommune do? Our directory classifies Evommune, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Evommune? The ISIN recorded for Evommune, Inc. is US30054Y1073. Does aibio.space cover Evommune? aibio.space lists Evommune, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Evommune incorporated? SEC records list its state or country of incorporation as DE. What was Evommune's revenue last year? $13.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Evommune profitable? Evommune, Inc. reported a net loss of $68.9 million for the fiscal year ended Dec 31, 2025, and used $76.4 million of cash in operations, per its annual report to the SEC. How much does Evommune spend on research and development? $74.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Evommune have? $200.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Evommune Members talk about Evommune (EVMN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Evommune, newest first. Each line links the filing it comes from. 1. 2026-09-08 Restructuring After top-line Phase 2b results, Evommune said it would stop developing EVO756 for atopic dermatitis and expects cash and investments to fund operations into 2029 under its revised plans. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm) 2. 2026-04-24 Financing Evommune filed the selling-stockholder resale prospectus; issuer proceeds from resales were excluded. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526177356/d127341d424b3.htm) 3. 2026-04-17 Financing Evommune filed a Form S-1 for resale registration; this is a filing date rather than a verified effectiveness date. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526161516/d127341ds1.htm) 4. 2026-03-05 Going concern The annual report said management plans alleviated earlier substantial doubt. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) 5. 2026-02-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/evmn-ex99_1.htm) 6. 2026-02-12 Financing Evommune agreed a common-stock private placement with approximately $125 million estimated gross proceeds. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/evmn-20260212.htm) 7. 2025-11-07 Financing The initial public offering closed, alongside charter and bylaw amendments. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312525272282/d38367d8k.htm) 8. 2025-11-06 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312525270066/d771358d424b4.htm) 9. 2025-10-17 Reverse split Evommune completed a pre-IPO one-for-8.5180 common-stock reverse split. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) 10. 2025-10-09 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312525235673/d771358ds1.htm) 11. 2025-06-27 Financing Evommune issued the second tranche of Series C preferred shares for $65.3 million gross. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) ## Investor questions about Evommune ### What was the latest reported cash and investment balance? The company reported $288.0 million in total cash, cash equivalents and investments at 2026-06-30. This includes long-term investments and is not a cash-only figure. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm) ### What is the latest company-stated funding horizon? A later filing said revised business plans were expected to be funded into 2029. The estimate is conditional and does not give a precise exhaustion date. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm) ### Did the latest annual report leave substantial doubt unresolved? The annual report said management implemented plans that alleviated earlier substantial doubt. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) ### Has Evommune completed a reverse split? It completed a one-for-8.5180 reverse split before the IPO. No exchange-deficiency rationale is verified for that action. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) ### What is the listing venue? The latest quarterly cover identifies the New York Stock Exchange and the EVMN symbol. No open deficiency has been verified in this research. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm) ### Did the company arrange a private placement? It agreed a common-stock placement at $27.88 per share. Later periodic reports disclose the related proceeds. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526049888/evmn-20260212.htm) ### Does the resale prospectus bring new cash to the company? The prospectus says the issuer will receive no proceeds from the covered shareholder resales. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526177356/d127341d424b3.htm) ### Who is the auditor? The latest annual audit is signed by BDO USA, P.C. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/evmn-20251231.htm) ### Was a chief financial officer purchase disclosed? A Form 4 reports a purchase by chief financial officer Kyle Carver and his agreement to pay the issuer the matched short-swing profit of $10,160. It does not prove the payment was received. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000175707226000007/xslF345X06/primarydocument.xml) ### Is a class action verified in the latest quarterly filing? The latest quarterly filing states no material legal proceeding was pending or threatened at its reporting date. This research does not certify absence across every court or later date. [Source](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:EVMN on TradingView](https://www.tradingview.com/symbols/NYSE-EVMN/). ## SEC filings and registration - **SEC name**: Evommune, Inc. - **CIK**: 2044725 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: EVMN (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1891 PAGE MILL RD, PALO ALTO, CA - **Phone**: (650) 223-7745 - **Shares outstanding**: 36,292,113 as of 2026-08-04 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/evmn-20260923.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526391390/evmn-20260915.htm) filed 2026-09-15 - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm) filed 2026-09-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/evmn-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-20260731.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526286918/evmn-20260629.htm) filed 2026-06-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002044725), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Evommune, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker EVMN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Evommune, Inc. - **Ticker**: EVMN - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US30054Y1073 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-EVMN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/evommune/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Evommune (EVMN) news: IPO and offering", 2026-10-31, https://aibio.space/companies/evommune/